IL6ST, a biomarker of endocrine therapy response, has potential in identifying a subgroup of women with ER plus DCIS who are more likely to benefit from adjuvant endocrine therapy

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >IL6ST, a biomarker of endocrine therapy response, has potential in identifying a subgroup of women with ER plus DCIS who are more likely to benefit from adjuvant endocrine therapy

【24h】

IL6ST, a biomarker of endocrine therapy response, has potential in identifying a subgroup of women with ER plus DCIS who are more likely to benefit from adjuvant endocrine therapy

机译：IL6St，内分泌治疗反应的生物标志物，具有潜力，旨在鉴定患有ER的妇女的亚组，以及更容易受益于佐剂内分泌治疗的DCIS

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
专利

1. IL6ST, a biomarker of endocrine therapy response, has potential in identifying a subgroup of women with ER plus DCIS who are more likely to benefit from adjuvant endocrine therapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：IL6St，内分泌治疗反应的生物标志物，具有潜力，旨在鉴定患有ER的妇女的亚组，以及更容易受益于佐剂内分泌治疗的DCIS
2. Adjuvant endocrine therapy for postmenopausal women with ER positive breast cancer: tailoring therapy based on tumors and patients [J] . Burstein H. J. The Breast : . 2017,第期

机译：辅助内分泌治疗患有ER正乳腺癌的绝经后妇女：基于肿瘤和患者的剪裁治疗
3. Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy [J] . Ivana Sestak Breast care . 2017,第3期

机译：鉴定生物标志物以选择适合扩展辅助内分泌治疗的早期乳腺癌患者
4. A Single Tube Screening of Endocrine Therapy Resistance ESR1 Mutations in ER-Positive Breast Cancer [C] . Akihiro Tsuyada, Shunsuke Nakano, Toshimitsu Ichijo, International Molecular Medicine Tri-Conference. . 2016

机译：ER阳性乳腺癌内分泌治疗抗ESR1突变的单管筛选
5. Adherence to Adjuvant Endocrine Therapy among Women Diagnosed with Early Breast Cancer. [D] . Farias, Albert. 2015

机译：在诊断为早期乳腺癌的女性中坚持辅助内分泌治疗。
6. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93 [O] . Olivia Pagani, Shari Gelber, Edda Simoncini, -1

机译：对于高度内分泌反应性淋巴结阳性的乳腺癌接受内分泌治疗的绝经后妇女辅助化疗是否有益？国际乳腺癌研究小组第VII和12-93号试验
7. DCIS II trial: a randomised trial testing observation (no radiotherapy) against radiotherapy in women with low-risk completely excised oestrogen receptor (ER) positive ductal carcinoma in situ (DCIS) of the breast on adjuvant endocrine therapy. [O] . Yarnold, J., Bundred, N., Dewar, J., 2004

机译：DCIs II试验：对患有低风险完全切除的雌激素受体（ER）阳性导管原位癌（DCIs）的妇女进行辅助内分泌治疗的放射治疗的随机试验观察（无放射治疗）。

IL6ST, a biomarker of endocrine therapy response, has potential in identifying a subgroup of women with ER plus DCIS who are more likely to benefit from adjuvant endocrine therapy

著录项

引文网络

相似文献

相关主题

期刊订阅